Invest in a Cure for Diabetes

We are at the stage of preparing an IND (Investigational New Drug) submission; we’re on the cusp of starting human clinical trials.

Regenerative Medical Solutions has the best team in the industry. Dr. Jon Odorico is the Scientific Founder of RMS and is known for his research and practical experience in the field.

Dr. Odorico is a revered Professor in the Department of Surgery, Division of Organ Transplantation, at the University of Wisconsin-Madison School of Medicine and Public Health.

Additionally, he is certified by the American Board of Surgery and has vast experience completing pancreas transplants, islet cell transplants, multi-organ transplants, and more surgical procedures.

On our Leadership page, you can learn more about Dr. Odorico, the numerous awards he has won, and the publications he has contributed to.

Our Scientific Founder, Dr. Odorico, played a key role in the first isolation and culturing of stem cells in the mid-1990s at the University of Wisconsin-Madison. This work was hailed as a major scientific breakthrough and featured on the cover of Time Magazine. 

Additionally, Dr. Odorico is a successful pancreatic and islet transplant surgeon with over 25 years of experience curing people with diabetes using cadaver islets. Cadaver islets come from human donors, so there are not enough islets available to treat every patient. Unfortunately, this existing process also requires the use of immunosuppressants; our new prospective cure does not have either of these limitations, and this existing method acts as proof of concept for our new technology. We believe our team and experience make RMS a great option for anyone looking to invest in biotech.

Competitors are working on similar cures for diabetes, but the current clinical competitor requires the patient to take anti-rejection drugs, which can lead to complications. The side effects of taking anti-rejection drugs range from headaches to gastrointestinal issues, osteoporosis, an increased risk of developing cancer, and even potential complications leading to death.

Yes, we plan to be acquired by a major pharmaceutical company once an initial Phase I human clinical trial is complete, if not before. An equivalent biotech company was recently bought for approximately $950 million at a similar stage of development as RMS is now. That competitive company was acquired before any human studies were initiated. We understand that investors need to keep exit strategies in mind when looking for biotech companies to invest in and are happy to discuss this further.